Wendy Verret

home / authors / wendy-verret

Articles

20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

Sara M. Tolaney, MD, MPH;Aditya Bardia, MD, MPH;Frederik Marmé;Javier Cortés, MD;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Oh Kyu Yoon;Hao Wang;Wendy Verret;Hope S. Rugo, MD
August 8th 2024
53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Frederik Marmé;Javier Cortes;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Hao Wang;Wendy Verret;Sara M. Tolaney, MD, MPH
April 27th 2023

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin
Published: May 27th 2011 | Updated: November 21st 2024
A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: November 21st 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma
Published: April 21st 2021 | Updated: November 21st 2024
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma